Drug
Dolutegravir
Dolutegravir: highest development phase Approved, developed by Aurobindo, Shionogi. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Aurobindo, Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE | Approved | |
| dolutegravir NCT01328041 | Phase 3 | Infection, Human Immunodeficiency Virus |
| Dolutegravir NCT01499199 | Phase 3 | Infection, Human Immunodeficiency Virus |
| Dolutegravir 50 mg NCT01353716 | Phase 1 | Infection, Human Immunodeficiency Virus |
Latest
No recent events.
Follow Dolutegravir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.